ClinicalTrials.Veeva

Menu

Randomized Trial of Mobilized Blood/Marrow Versus Blood Transplant

P

Peking University

Status

Withdrawn

Conditions

Leukemia

Treatments

Procedure: transplant with PBSCs

Study type

Interventional

Funder types

Other

Identifiers

NCT01617473
PUPH IRB [2012] (27)

Details and patient eligibility

About

The use of peripheral blood stem cells(PBSCs) is rapidly growing in the allogeneic transplantation setting as an alternative to bone marrow (BM).It was found that the use of PBSCs is associated with faster hematologic recovery but have yielded differing results regarding the incidence of graft-versus-host-disease (GVHD) and relapse.

The study hypothesis:

transplantation of mobilized PBSC to haploidentical donor with standard-risk leukemia had comparable engraftment and non-relapse mortality to mobilized BM combined with PBSCs

Full description

The donors were primed with granulocyte-colony stimulating factor (G-CSF) injected subcutaneously for five consecutive days. In the trial group, the PBSCs were harvested on the fourth and fifth day;in the control group, the bone marrow cells were harvested on the fourth day and the PBSCs were harvested on the fifth day.

Sex

All

Ages

2 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Standard risk of Recipients of haploidentical stem cell transplantation with myeloablative conditioning regimens

Exclusion criteria

  • Active, uncontrolled infection

Trial design

0 participants in 2 patient groups

procedure/surgery
Experimental group
Description:
transplant with G-CSF mobilized PBSCs
Treatment:
Procedure: transplant with PBSCs
other
No Intervention group
Description:
no intervention after transplant with mobilized BMPB

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems